Results 31 to 40 of about 1,254,012 (356)

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors [PDF]

, 2017
Background Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy have limited therapeutic options.
Al‐nahhas, A, Ansquer, C, Anthony, L, Azevedo, I, Baudin, E, Baum, Rp, Baum, Rp, Benson, A, Benson, Ab, Berlin, J, Berlin, J, Bodei, L, Brianzoni, E, Bushnell, D, Bushnell, D, Caplin, M, Caplin, M, Chasen, B, Chiara Grana, M, Courbon, F, DELLE FAVE, Gianfranco, Delpassand, E, Delpassand, E, El Haddad, G, Erion, Jl, Freemantle, N, Garbus, S, Giammarile, F, Grande, E, Grande, E, Grossman, A, Hendifar, A, Hendifar, A, Hobday, T, Hobday, T, Jacene, H, Krenning, E, Kulkarni, Hr, Kulke, M, Kulke, Mh, Kunz, Pl, Kvols, L, Kwekkeboom, D, Lebtahi, R, Lopera Sierra, M, Manoharan, P, Mariani, G, Metz, D, Mittra, E, Mittra, E, Mora, J, Mora, J, Morse, M, O'Dorisio, Tm, Pavel, M, Pavel, M, Reed, N, Reed, N, Rindi, G, Ruszniewski, P, Ruszniewski, P, Santoro, P, Scheidhauer, K, Schipper, M, Seregni, E, Seregni, E, Severi, S, Srirajaskanthan, R, Srirajaskanthan, R, Strosberg, J, Strosberg, J, Sundin, A, Taieb, D, Thevenet, T, Van Cutsem, E, Van Cutsem, E, Weber, M, Wolin, E, Wolin, E, Yao, J, Yao, J., Öberg, K, Öberg, K   +82 more
core   +1 more source

The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

Cancer Cell International, 2021
Purpose An increasing number of studies have reported a significant association between long non-coding RNAs (lncRNAs) dysregulation and pancreatic cancers.
Elahe Seyed Hosseini, Ali Nikkhah, Amir Sotudeh, Marziyeh Alizadeh Zarei, Fatemeh Izadpanah, Hossein Nikzad, Hamed Haddad Kashani   +6 more
doaj   +1 more source

A phase II study of capecitabine and oxalplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract [PDF]

, 2016
Background: Advanced biliary tract carcinomas are associated with a poor prognosis, and palliative chemotherapy has only modest benefit. This multi-centre phase II study was conducted to determine the efficacy of capecitabine in combination with ...
E. Soulis, F. Y. Coxon, J. S. Graham, K. Boyd, L. R. Wall, M. Highley, M. M. Eatock, P. Bützberger-Zimmerli, S. Harden, T. R. J. Evans, T. S. Maughan   +10 more
core   +1 more source

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. [PDF]

, 2016
BACKGROUND: Outcome of low-grade glioma (WHO grade II) is highly variable, reflecting molecular heterogeneity of the disease. We compared two different, single-modality treatment strategies of standard radiotherapy versus primary temozolomide ...
Balana, C., Baumert, B.G., Brandes, A.A., Bravo-Marques, J., Bromberg, J.E., Capper, D., Chinot, O., Clement, P.M., Dhermain, F., Dif, N., Enting, R., Feuvret, L., Gijtenbeek, J.M., Gorlia, T., Hartmann, C., Hassel, M.B., Hegi, M.E., Hoang-Xuan, K., Kantor, G., Kros, J.M., Kurscheid, S., Lacombe, D., Marosi, C., Mason, W.P., Nordal, R.A., Rees, J., Reijneveld, J.C., Reni, M., Rossiter, J.P., Ryan, G., Stupp, R., Taphoorn, M.J., Thiessen, B., Tzuk-Shina, T., van den Bent, M.J., von Deimling, A., Wick, W.   +36 more
core   +6 more sources

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer

Frontiers in Nutrition, 2023
BackgroundThe purpose of this study was to investigate the prognostic significance of sarcopenia diagnosed based on anthropometric equations for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC).MethodsA ...
Hailun Xie, Hailun Xie, Lishuang Wei, Shunhui Gao, Shunhui Gao, Mingxiang Liu, Mingxiang Liu, Yanren Liang, Yanren Liang, Guanghui Yuan, Guanghui Yuan, Qiwen Wang, Qiwen Wang, Yansong Xu, Shuangyi Tang, Jialiang Gan, Jialiang Gan   +16 more
doaj   +1 more source

Экструдируемые гетеромодульные полимер-полимерные композиты на основе сверхвысокомолекулярной матрицы [PDF]

, 2005
Purpose:The aim of the present study was to define gene expression profiles of noninvasive and invasive bladder cancer, to identify potential therapeutic or screening targets in bladder cancer, and to define genetic changes relevant for tumor progression
Hartmann, Arndt, Herr, Alexander, Knüchel-Clarke, Ruth, Pilarsky, Christian, Rosenthal, André, Simon, Ronald, Stöhr, Robert, Wild, Peter Johannes, Wissmann, Christoph, Zaak, Dirk   +9 more
core   +1 more source

Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

Acta Oncologica
Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of
Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen   +10 more
doaj   +1 more source

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

The Application of Clinical Genetics, 2022
Naglaa S Elabd,1 Shimaa E Soliman,2 Moamena S Elhamouly,1 Suzy F Gohar,3 Ayman Elgamal,4 Mahmoud Magdy Alabassy,5 Haitham A Soliman,5 Abdelnaser A Gadallah,6 Osama D Elbahr,7 Ghada Soliman,3 Amany A Saleh2 1Tropical Medicine Department, Faculty of ...
Elabd NS, Soliman SE, Elhamouly MS, Gohar SF, Elgamal A, Alabassy MM, Soliman HA, Gadallah AA, Elbahr OD, Soliman G, Saleh AA   +10 more
doaj  

Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. [PDF]

, 2013
IntroductionEffective treatments for hormone-receptor-positive (HR(+)) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor (NSAI) therapy are needed. Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data
Arena, Francis P, Baselga, José, Burris, Howard A, Cahana, Ayelet, Campone, Mario, Erdkamp, Frans, Feng, Wentao, Gnant, Michael, Harb, Wael A, Hortobagyi, Gabriel N, Lebwohl, David, Melichar, Bohuslav, Noguchi, Shinzaburo, Petrakova, Katarina, Piccart, Martine, Pistilli, Barbara, Pritchard, Kathleen I, Rugo, Hope S, Taran, Tetiana, Yardley, Denise A   +19 more
core   +2 more sources

Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. [PDF]

, 2018
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic leukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with ...
Bairey, Osnat, Barr, Paul M., Bartlett, Nancy L., Burger, Jan A., Coutre, Steven E, Devereux, Stephen, Ghia, Paolo, Grosicki, Sebastian, Hillmen, Peter, James, Danelle, Kipps, Thomas J, Li, Jianyong, McCarthy, Helen, Moreno, Carol, Offner, Fritz, Owen, Carolyn, Robak, Tadeusz, Simpson, David, Styles, Lori, Tedeschi, Alessandra, Universitat Autònoma de Barcelona, Zhou, Cathy   +21 more
core   +5 more sources